نتایج جستجو برای: tp53 protein

تعداد نتایج: 1240012  

2018
Rui Huang Xiwen Liao Qiaochuan Li

Background Tumor protein p53 (TP53) mutations are not only a risk factor in acute myeloid leukemia (AML) but also a potential biomarker for individualized treatment options. This study aimed to investigate potential pathways and genes associated with TP53 mutations in adult de novo AML. Methods An RNA sequencing dataset of adult de novo AML was downloaded from The Cancer Genome Atlas database...

Journal: :Ukrainian biochemical journal 2014
S V Danilovskyi D O Minchenko O S Moliavko O V Kovalevska L L Karbovskyi O H Minchenko

Endoplasmic reticulum stress and hypoxia are necessary components of malignant tumors growth and suppression of ERN1 (from endoplasmic reticulum to nuclei-1) signalling pathway, which is linked to the apoptosis and cell death processes, significantly decreases proliferative processes. Glioma cells with ERN1 knockdown were used in order to investigate the effect of ERNI blockade on the expressio...

2017
Tao Lu Paul Kim Yu Luo

Tp53, a stress response gene, is involved in diverse cell death pathways and its activation is implicated in the pathogenesis of Parkinson's disease. However, whether the neuronal Tp53 protein plays a direct role in regulating dopaminergic (DA) neuronal cell death or neuronal terminal damage in different neurotoxicant models is unknown. In our recent studies, in contrast to the global inhibitio...

2016
Joonil Jung Joon Sang Lee Mark A. Dickson Gary K. Schwartz Axel Le Cesne Andrea Varga Rastilav Bahleda Andrew J. Wagner Edwin Choy Maja J. de Jonge Madelyn Light Steve Rowley Sandrine Macé James Watters

In tumours that harbour wild-type p53, p53 protein function is frequently disabled by the mouse double minute 2 protein (MDM2, or HDM2 in humans). Multiple HDM2 antagonists are currently in clinical development. Preclinical data indicate that TP53 mutations are a possible mechanism of acquired resistance to HDM2 inhibition; however, this resistance mechanism has not been reported in patients. U...

2016
Gilles Gadea Nikola Arsic Kenneth Fernandes Alexandra Diot Sébastien M Joruiz Samer Abdallah Valerie Meuray Stéphanie Vinot Christelle Anguille Judit Remenyi Marie P Khoury Philip R Quinlan Colin A Purdie Lee B Jordan Frances V Fuller-Pace Marion de Toledo Maïlys Cren Alastair M Thompson Jean-Christophe Bourdon Pierre Roux

TP53 is conventionally thought to prevent cancer formation and progression to metastasis, while mutant TP53 has transforming activities. However, in the clinic, TP53 mutation status does not accurately predict cancer progression. Here we report, based on clinical analysis corroborated with experimental data, that the p53 isoform Δ133p53β promotes cancer cell invasion, regardless of TP53 mutatio...

2016
Ji-Yeon Kim Kyunghee Park Hae Hyun Jung Eunjin Lee Eun Yoon Cho Kwang Hee Lee Soo Youn Bae Se Kyung Lee Seok Won Kim Jeong Eon Lee Seok Jin Nam Jin Seok Ahn Young-Hyuck Im Yeon Hee Park

PURPOSE TP53, the most frequently mutated gene in breast cancer, is more frequently altered in HER2-enriched and basal-like breast cancer. However, no studies have clarified the role of TP53 status as a prognostic and predictive marker of triple-negative breast cancer (TNBC). MATERIALS AND METHODS We performed p53 immunohistochemistry (IHC), nCounter mRNA expression assay, and DNA sequencing ...

2014
Rongwei Sun Xudong Wang Huijun Zhu Haijun Mei Wei Wang Shu Zhang Jianfei Huang

Lysosomal associated membrane protein 3 (LAMP3) is a newly identified tumor-specific protein. It is a downstream target gene of tumor suppressor TP53 and its expression has been associated with hypoxia-induced metastasis and poor overall survival in cervical and breast cancers. However, little is known of LAMP3 protein expression in gastrointestinal cancer and its prognostic value. We determine...

2015
Yasuki Hori Katsuyuki Miyabe Michihiro Yoshida Takahiro Nakazawa Kazuki Hayashi Itaru Naitoh Shuya Shimizu Hiromu Kondo Yuji Nishi Shuichiro Umemura Akihisa Kato Hirotaka Ohara Hiroshi Inagaki Takashi Joh

Single-nucleotide polymorphisms (SNPs) of TP53 (codon 72, rs1042522) and MDM2 promoter (SNP 309, rs2279744) have been associated with risk for various human cancers. However, studies analyzing these polymorphisms in pancreatic ductal adenocarcinoma (PDAC) are lacking. We investigated TP53 codon 72 and MDM2 SNP 309 polymorphisms in 32 patients with PDAC, 16 patients with chronic pancreatitis (CP...

2012
Paulina M. Wojnarowicz Kathleen Klein Oros Michael C. J. Quinn Suzanna L. Arcand Karen Gambaro Jason Madore Ashley H. Birch Manon de Ladurantaye Kurosh Rahimi Diane M. Provencher Anne-Marie Mes-Masson Celia M. T. Greenwood Patricia N. Tonin

High-grade ovarian serous carcinomas (HGSC) are characterized by TP53 mutations and non-random patterns of chromosomal anomalies, where the nature of the TP53 mutation may correlate with clinical outcome. However, the frequency of common somatic genomic events occurring in HGSCs from demographically defined populations has not been explored. Whole genome SNP array, and TP53 mutation, gene and p...

2012
Min-Bin Chen Ya-Qun Zhu Jun-Ying Xu Li-Qiang Wang Chao-Ying Liu Zhang-Yi Ji Pei-Hua Lu

BACKGROUND Numerous studies have yielded inconclusive results regarding the relationship between tumor suppressor protein TP53 overexpression and/or TP53 gene mutations and the response to neoadjuvant chemotherapy in patients with breast cancer. The purpose of the current study was therefore to evaluate the relationship between TP53 status and response to chemotherapy in breast cancer. METHOD...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید